1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66CFD1FD1C20B05B400258AD90032AA4D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/rare-disease-field-medical-excellence-benchmark-top-12-global-markets-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Field Medical Excellence

Rare Disease Field Medical Excellence Benchmark of Top 12 Global Markets: Establishing Standards for High Performance & Impact

ID: POP-373


Features:

10 Info Graphics

51 Data Graphics

410+ Metrics

7 Narratives


Pages: 70


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
With limited patient populations and complex diagnostic pathways, rare disease manufacturers face unique challenges in optimizing their field medical teams to deliver tailored support to diverse local teams across global markets. Thus, the efficiency and ingenuity of MSL teams becomes paramount in overcoming these challenges and ensuring optimal support for healthcare providers and key opinion leaders.

Best Practices, LLC undertook this benchmarking research to provide a roadmap for excellence in rare disease field medical operations on a global scale. This report will empower rare disease field medical excellence leaders to craft robust frameworks that drive consistency and high impact across key global regions — North America, Europe, APAC, LATAM, and MENA. This study offers strategic insights to improve KOL interactions, evaluate MSL performance, and align staffing footprints to meet the unique demands of the rare disease landscape.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC collated performance data and insights from Field Medical executives from rare disease companies around the world through a custom benchmark survey. Focused on rare disease field medical operations, the research drew insights from a diverse range of respondents and was meticulously segmented at regional levels.

Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Key topics covered in this report include:

  • Effective Rare Disease Field Performance Metrics
  • Developing a Rare Disease Field Medical Excellence Framework
  • Target and Engagement Levels of Key Opinion Leaders within the Rare Disease Segment
  • MSL Time Allocation for KOL Interactions and Internal Activities
  • Rare Disease Field Medical Staffing Footprint
  • Key Insights and Lessons Learned for Evaluating the Impact of MSLs in Rare Diseases

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Value Assigned to F2F Interactions in Europe: A majority of competitors (67%) reward F2F interactions in rare diseases, but not in other therapeutic areas.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & Expectations in Rare DiseasesPg. 3-19
II.
North America: Regional Data Segmented by Rare Disease Therapeutic AreaPg. 20-29
III.
Europe: Regional Data Segmented by Rare Disease Therapeutic AreaPg. 30-39
IV.
APAC: Regional Data Segmented by Rare Disease Therapeutic AreaPg. 40-49
V.
LATAM: Regional Data Segmented by Rare Disease Therapeutic AreaPg. 50-59
VI.
MENA: Regional Data Segmented by Rare Disease Therapeutic AreaPg. 60-69
VII.
About Best Practices, LLCPg. 70

    List of Charts & Exhibits

    I. Executive Summary: Laying the Foundation for Global Field Medical Performance Standards & Expectations in Rare Diseases

    • Business objectives and research methodology
    • Regions and therapeutic areas probed in this benchmark research
    • Benchmark partner companies
    • Global benchmarking findings: Quick takeaways and recommendations
    • Global benchmarking findings: Summary of rare disease regional data
    • Global field scorecard: Benchmarking rare disease engagement metrics across all five regions
      Most effective and utilized field metrics for demonstrating the value and impact of MSLs
    • Metrics leveraged to evaluate MSL performance
    • Lessons learned around MSL time allocation in field and on external activities
    • Defining “monthly interactions”
    • Distinguishing an "actionable" insight from other kinds of insights
    • Definitions of "actionable insights" from the field
    • Crafting a global field medical excellence framework

    II. North America: Regional Data Segmented by Rare Disease Therapeutic Area

    • North America field scorecard: Benchmarking rare disease engagements
    • Average total panel size supported by an individual rare disease MSL in North America
    • Average number of monthly KOL/HCP and F2F meetings in North America – rare disease segment
    • Value assigned to each interaction type on the rare disease MSL scorecard (North America)
    • Engagement metrics for non-tiered rare disease KOLs in North America
    • Average annual field presence of rare disease MSLs in North America
    • Time spent by rare disease MSLs on external, internal, and logistics activities in North America
    • Weekly rare disease MSL time allocation across activity streams in North America
    • Rare disease MSL engagement mix in North America
    • Rare disease field medical staffing footprint in North America

    III. Europe: Regional Data Segmented by Rare Disease Therapeutic Area

    • Europe field scorecard: Benchmarking rare disease engagements
    • Average number of tiered vs. non-tiered KOLs per rare disease MSL in Europe
    • Monthly KOL and F2F interactions in Europe – rare disease segment
    • Weighting criteria for various interaction types on the rare disease MSL scorecard (Europe)
    • Metrics for engaging non-tiered rare disease KOLs in Europe
    • Average rare disease MSL time in the field (days per year) in Europe
    • Percentage of rare disease MSL time spent on external, internal, and logistics activities in Europe
    • Weekly rare disease MSL time allocation for each activity stream in Europe
    • Percentage of overall rare disease targets classified as KOLs, HCPs, payers, or other external stakeholders in Europe
    • Rare disease field medical staffing footprint in Europe

    IV. APAC: Regional Data Segmented by Rare Disease Therapeutic Area

    • APAC field scorecard: Benchmarking rare disease engagements
    • Average total panel size supported by an individual rare disease MSL in the APAC region
    • Average number of monthly KOL/HCP and F2F meetings in the APAC region
    • Value assigned to each interaction type on the rare disease MSL scorecard (APAC region)
    • Engagement metrics for non-tiered KOLs in the APAC region
    • Average annual field presence of rare disease MSLs in the APAC region
    • Time spent by rare disease MSLs on external, internal, and logistics activities in the APAC region
    • Weekly rare disease MSL time allocation across activity streams in the APAC region
    • Rare disease MSL engagement mix in the APAC region
    • Average number of rare disease field staff members in the APAC region

    V. LATAM: Regional Data Segmented by Rare Disease Therapeutic Area

    • LATAM field scorecard: Benchmarking rare disease engagements
    • Average number of tiered vs. non-tiered KOLs per rare disease MSL in the LATAM region
    • Monthly KOL and F2F interactions in the LATAM region – rare disease segment
    • Weighting criteria for various interaction types on the rare disease MSL scorecard (LATAM region)
    • Metrics for engaging non-tiered KOLs in the LATAM region
    • Average rare disease MSL time in the field (days per year) in the LATAM region
    • Percentage of rare disease MSL time spent on external, internal, and logistics activities in the LATAM region
    • Weekly rare disease MSL time allocation for each activity stream in the LATAM region
    • Percentage of overall rare disease targets classified as KOLs, HCPs, payers, or other external stakeholders in the LATAM region
    • Rare disease field medical staffing footprint in the LATAM region

    VI. MENA: Regional Data Segmented by Rare Disease Therapeutic Area

    • MENA field scorecard: Benchmarking rare disease engagements
    • Average number of tiered vs. non-tiered KOLs per rare disease MSL in the MENA region
    • Monthly KOL and F2F interactions in the MENA region – rare disease segment
    • Weighting criteria for various interaction types on the rare disease MSL scorecard (MENA region)
    • Metrics for engaging non-tiered rare disease KOLs in the MENA region
    • Average rare disease MSL time in the field (days per year) in the MENA region
    • Percentage of rare disease MSL time spent on external, internal, and logistics activities in the MENA region
    • Weekly rare disease MSL time allocation for each activity stream in the MENA region
    • Percentage of overall rare disease targets classified as KOLs, HCPs, payers, or other external stakeholders in the MENA region
    • Rare disease field medical staffing footprint in the MENA region